The cash will support mid-stage trials of a prospect the company claims to have “best-in-disease” potential treating major depressive disorder.

The cash will support mid-stage trials of a prospect the company claims to have “best-in-disease” potential treating major depressive disorder.

Draig Therapeutics Closes Oversubscribed $65 Million Series B to Accelerate Development of Highly Specific AMPA and GABAA Receptor Modulators in Neuropsychiatric Disorders